Pfizer (PFE) Financials: History & Chart

Pfizer Inc. (PFE)PFEPfizer Inc.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY

75,000 employees

www.pfizer.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Albert Bourla

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	63.31B	14.45B	17.56B	16.65B	14.65B	13.71B	N/A	17.76B	17.70B
Cost of Goods Sold	19.41B	4.73B	5.27B	4.17B	5.23B	3.89B	N/A	4.79B	6.93B
Gross Profit	43.91B	9.72B	12.29B	12.48B	9.42B	9.83B	N/A	12.97B	10.77B
Gross Profit Margin	69.3%	67.3%	70.0%	74.9%	64.3%	71.7%	N/A	73.0%	60.8%
Total Operating Expenses	29.06B	5.69B	8.60B	8.93B	5.84B	5.20B	N/A	7.24B	5.80B
Research & Development	12.42B	2.63B	3.42B	3.94B	2.44B	2.18B	N/A	3.02B	2.56B
Selling, General & Administrative	13.28B	2.96B	3.73B	3.19B	3.40B	3.02B	N/A	4.23B	3.24B
Operating Income (EBIT)	14.85B	4.03B	3.69B	3.55B	3.58B	4.62B	N/A	5.72B	4.97B
Operating Margin	23.4%	27.9%	21.0%	21.3%	24.4%	33.7%	N/A	32.2%	28.1%
Income Before Tax (EBT)	7.91B	3.17B	-1.64B	3.33B	3.04B	2.78B	N/A	-10.00M	4.71B
Interest Income	575.00M	115.00M	166.00M	138.00M	156.00M	143.00M	N/A	170.00M	116.00M
Interest Expense	2.69B	668.00M	711.00M	652.00M	654.00M	654.00M	N/A	739.00M	783.00M
Other Income/Expense	-6.94B	-862.00M	-5.33B	-216.00M	-531.00M	-1.84B	N/A	-5.74B	-253.00M
Net Income	7.49B	2.69B	-1.65B	3.54B	2.91B	2.97B	N/A	403.00M	4.47B
Income Tax Expense	384.00M	461.00M	-2.00M	-216.00M	141.00M	-189.00M	N/A	-421.00M	234.00M
Net Profit Margin	11.8%	18.6%	-9.4%	21.3%	19.9%	21.6%	N/A	2.3%	25.3%
EBITDA	21.00B	5.21B	5.38B	5.21B	5.20B	6.24B	N/A	7.52B	6.72B
EBITDA Margin	33.2%	36.1%	30.6%	31.3%	35.5%	45.5%	N/A	42.3%	38.0%
Depreciation & Amortization	6.16B	1.18B	1.69B	1.66B	1.63B	1.62B	N/A	1.79B	1.75B
EPS Basic	1.31	0.47	-0.29	0.62	0.51	0.52	N/A	0.07	0.79
EPS Diluted	1.31	0.47	-0.29	0.62	0.51	0.52	N/A	0.07	0.78
Shares Outstanding	5.69B	5.69B	5.68B	5.68B	5.68B	5.67B	N/A	5.67B	5.67B
Diluted Shares Outstanding	5.73B	5.73B	5.69B	5.71B	5.71B	5.71B	N/A	5.70B	5.71B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	62.58B	63.63B	59.55B	100.33B	81.29B	41.65B	41.17B	53.65B
Cost of Goods Sold	18.57B	21.78B	29.21B	38.24B	34.41B	11.77B	12.62B	16.01B
Gross Profit	44.01B	41.85B	30.34B	62.09B	46.88B	29.88B	28.55B	37.64B
Gross Profit Margin	70.3%	65.8%	50.9%	61.9%	57.7%	71.7%	69.3%	70.2%
Total Operating Expenses	28.58B	25.36B	25.05B	24.54B	26.08B	20.80B	21.04B	22.35B
Research & Development	11.98B	10.74B	10.58B	11.43B	13.83B	9.39B	8.36B	7.97B
Selling, General & Administrative	13.35B	14.73B	14.47B	13.12B	12.25B	11.40B	12.67B	14.38B
Operating Income (EBIT)	15.44B	16.48B	5.29B	37.55B	20.79B	9.09B	7.51B	15.29B
Operating Margin	24.7%	25.9%	8.9%	37.4%	25.6%	21.8%	18.2%	28.5%
Income Before Tax (EBT)	7.52B	8.02B	1.06B	34.73B	24.31B	7.04B	11.48B	11.88B
Interest Income	603.00M	545.00M	1.62B	251.00M	36.00M	73.00M	225.00M	333.00M
Interest Expense	2.67B	3.09B	2.21B	1.24B	1.29B	1.45B	1.57B	1.32B
Other Income/Expense	-7.92B	-8.46B	-4.23B	-2.82B	3.52B	-2.05B	3.97B	-3.40B
Net Income	7.77B	8.02B	2.13B	31.36B	22.15B	9.16B	16.27B	11.15B
Income Tax Expense	-266.00M	-28.00M	-1.11B	3.33B	1.85B	370.00M	618.00M	706.00M
Net Profit Margin	12.4%	12.6%	3.6%	31.3%	27.2%	22.0%	39.5%	20.8%
EBITDA	20.34B	23.50B	11.58B	42.61B	25.98B	13.77B	13.31B	21.67B
EBITDA Margin	32.5%	36.9%	19.4%	42.5%	32.0%	33.1%	32.3%	40.4%
Depreciation & Amortization	4.91B	7.01B	6.29B	5.06B	5.19B	4.68B	5.79B	6.38B
EPS Basic	1.36	1.42	0.38	5.59	3.95	1.65	2.92	1.90
EPS Diluted	1.36	1.41	0.37	5.47	3.88	1.63	2.87	1.87
Shares Outstanding	5.68B	5.66B	5.64B	5.61B	5.60B	5.55B	5.57B	5.87B
Diluted Shares Outstanding	5.69B	5.70B	5.71B	5.73B	5.71B	5.63B	5.67B	5.98B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.